-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company has ranked among the top 50 Chinese chemical pharmaceutical enterprises.
Category:
Time：2019-08-17
On July 15, the 2019 National Pharmacy Week and the China Pharmaceutical Innovation and Development Conference officially opened in Jinan, Shandong Province. During the conference, the 2018 Top 100 Chinese Pharmaceutical Industry Rankings were officially released. Thanks to its solid R&D and production capabilities as well as its stable market promotion efforts, the company was successfully included in the sub-ranking “Top 100 Chinese Chemical Pharmaceutical Enterprises 2018” of the 2018 Top 100 Chinese Pharmaceutical Industry Rankings, ranking 50th. The 2018 Top 100 Chinese Pharmaceutical Industry Rankings were organized by the Minew Research Institute, with the expert committee for the Top 100 Chinese Pharmaceutical Industry Rankings, and were exclusively developed and operated by Minew.com in China.
On July 15, the 2019 National Pharmacy Week and the China Pharmaceutical Innovation and Development Conference officially opened in Jinan, Shandong. During the conference, the list of China’s Top 100 Pharmaceutical Companies for 2018 was officially released. Thanks to its solid R&D and production capabilities as well as its stable market promotion efforts, the company successfully made it onto the sub-list “Top 100 Chinese Chemical Pharmaceutical Enterprises Ranking for 2018” within the “China Pharmaceutical Industry Top 100 List for 2018,” ranking 50th.
The 2018 Top 100 Chinese Pharmaceutical Industry List was compiled by the Expert Committee of the China Top 100 Pharmaceutical Industry Rankings, organized by the Minenet Research Institute. Relying on the three-terminal and six-market terminal structure database—exclusively developed and operated by Minenet for many years—the ranking evaluates pharmaceutical companies from two key dimensions: innovation-driven force and professional promotion capability. The “Top 100 Chinese Pharmaceutical Industry List,” hosted by the Southern Institute of Pharmaceutical Economics and Biao Dian Information Group, is often referred to as the “Oscars of China’s Pharmaceutical Industry” and is one of the most closely watched and authoritative pharmaceutical rankings in China. The top 100 enterprises represent the backbone of China’s pharmaceutical industry and embody the highest level of China’s pharmaceutical manufacturing sector.
As an outstanding representative of China’s pharmaceutical enterprises, our company has always been committed to brand building, adhering to the business philosophy of “serving the people with quality and integrity as our foundation.” We take it as our mission to “make high-quality medicines for the betterment of humanity,” and have cultivated an exceptional brand culture underpinned by superior product quality and thoughtful, comprehensive services. In recent years, the company has leveraged innovation to enhance its brand value: each year brings new projects and new products launched into the market, ensuring steady and sustained growth in economic performance. On one hand, we continuously strengthen our cost advantages through management and technological innovations; on the other hand, by innovating our business philosophy and focusing on the supply end, we’ve achieved counter-trend growth, taking a crucial step from adapting to the new normal to leading it. In recent years, our company has consistently pursued a development strategy that aligns innovation, quality, and branding, enabling us to remain steadily ranked among the top 100 pharmaceutical companies and become a leading enterprise in the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license